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The protein REPS2 is implicated in growth factor
receptor-mediated endocytosis and signalling, and its
expression is downregulated in androgen-independent
prostate cancer cells. Herein, the NF-jB subunit p65 is
identified as a human REPS2 protein partner, interacting
with the EH domain of REPS2. Using crystal structure
data from literature and experimental data from yeast and
mammalian two-hybrid analysis, the results indicate that
the NPF-motif in p65 acts as binding site for the EH
domain in REPS2. However, in cultured prostate cancer
cells, the REPS2–p65 interaction is triggered upon
stimulation with phorbol ester (PMA). This indicates that
PMA-sensitive signalling pathways can affect the inter-
action between REPS2 and p65. During prostate cancer
progression from androgen-dependent to androgen-inde-
pendent growth, downregulation of REPS2 is accompa-
nied by upregulation of NF-jB activity. This might involve
loss of REPS2–p65 interaction, which would lead to
increased NF-jB activity. Androgen-deprivation causes
apoptosis of prostate cancer cells, and activated NF-jB is
a known inhibitor of apoptosis. Hence, decreased expres-
sion of REPS2 might be a key factor, causing prostate
cancer cells to become resistant to induction of apoptosis
by androgen deprivation.
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Introduction
Growth of advanced prostate cancer initially is con-
trolled by androgen ablation therapy. Reduction of the
circulating androgen level to almost zero induces
apoptosis of hormone-dependent normal prostate cells,
and also induces apoptosis of prostate cancer cells.
However, remaining prostate cancer cells progress from
androgen-dependent towards androgen-independent
growth, within a few years, and this means transition
to uncontrollable cancer. To study molecular and
cellular mechanisms involved in this transition, we have
conducted a differential display PCR between androgen-
dependent and androgen-independent prostate cancer
cells (Chang et al., 1997). Clone JC19 was isolated as
a transcript expressed at a five-fold higher level in an
androgen-dependent prostate cancer cell line (LNCaP-
FGC), as compared to three androgen-independent
prostate cancer cell lines (LNCaP-LNO, PC3 and
DU145). Furthermore, using a panel of androgen-
dependent and androgen-independent human prostate
cancer xenografts, a similar change in JC19 expression
was observed (Chang et al., 1997). Clone JC19 was
identified to encode REPS2 (RALBP1-associated Eps
domain containing protein 2).
Although REPS2 is differentially expressed between
androgen-dependent and androgen-independent pros-
tate cancer cell lines, it is not androgen regulated (Chang
et al., 1997). Furthermore, the REPS2 gene is located on
the human X chromosome at Xp22, and transcribes into
a single mRNA of approximately 7000 base pairs. This
mRNA contains a maximum open reading frame
(ORF), which encodes a protein of 659 amino acids,
but on Western blot two REPS2 proteins were observed
(Oosterhoff et al., 2003). The 78 kDa protein, REPS2a,
is encoded by the maximal ORF that is present in the
REPS2 mRNA. The other protein, REPS2b, is encoded
by the same ORF but is shorter, with a molecular mass
of 58 kDa and consisting of amino acid residues 140–
659, because the second N-terminal methionine is used
as a translation start (Oosterhoff et al., 2003). REPS2
was initially named POB1 (Partner Of RalBP1) (Ikeda
et al., 1998), and identified as a 521-amino-acid protein
that binds to RalBP1 (Rac/CDC42 GTPase-activating
protein). The shorter form of REPS2 (REPS2b) is
identical to the POB1 protein, except that POB1 has an
additional glutamine residue inserted between amino
acids 181 and 182.
REPS2 contains at least three different regions
potentially involved in protein–protein interactions.
First, at the C-terminus there is a coiled-coil protein–
protein interaction domain, which is part of a larger
region (amino acids 513–659) that is involved in RalBP1
binding (Ikeda et al., 1998). Second, there are two
proline-rich motifs, PPTPPPRP (amino acids 476–483)
and PPPPALPPRP (amino acids 512–521), which are
putative binding sites for proteins containing an Src
homology 3 (SH3) domain. The protein Grb2, contain-
ing an SH3 domain, has been reported to bind to REPS2
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(Ikeda et al., 1998). Third, REPS2 contains one
imperfect Eps15 homology (EH) domain (amino acids
16–69) and one consensus EH domain (amino acids
265–366). EH domain proteins are thought to play a
role in receptor-mediated endocytosis (Santolini et al.,
1999), and for REPS2 it has been demonstrated that
the consensus EH domain binds Epsin and Eps15,
two proteins that are implicated in endocytosis
(Nakashima et al., 1999). In addition, it was shown
that deletion mutants of REPS2 can inhibit interna-
lization of EGF and insulin receptors (Nakashima
et al., 1999). Based on these observations, REPS2 is
thought to be involved in growth factor receptor
signalling and internalization. Recently, it was shown
that overexpression of REPS2 in prostate cancer
cells leads to induction of apoptosis (Oosterhoff et al.,
2003), which may point to an additional role for
REPS2 in cellular mechanisms other than receptor
internalization.
To study molecular and cellular aspects of the
possible role of REPS2 in the transition of prostate
cancer cells from androgen-dependent to androgen-
independent growth in more detail, experiments
were performed to identify novel protein partners of
REPS2. Using a human prostate cDNA expression
library, and yeast and mammalian two-hybrid strategies,
REPS2 was found to interact with the NF-kB subunit
RelA/p65.
Results
P65 and Clone4 were identified as binding partners
of REPS2
To identify proteins that interact with the REPS2
protein, a human prostate cDNA expression library
was screened with REPS2a (1–659) as a bait (Figure 1).
Herein, we report on two proteins that showed binding
to REPS2. One of the prey proteins that bound
the REPS2 bait appeared to be a large fragment of
the NF-kB subunit RelA/p65 protein (74–551). Since
the relevant functional domains of p65 are
located within this prey protein, the current clone was
used as the basis for our further investigations.
The second prey represented a large fragment of a
hypothetical protein (GenBank accession number
AF448860) and was named Clone4. In the present
study, REPS2–Clone4 interactions serve as a control for
the REPS2–p65 interaction.
The REPS2 EH domain binds to p65
To determine which part of REPS2 binds to p65 and
Clone4, different REPS2 variants (Figure 1) were used
in yeast two-hybrid analysis. Yeast strain AH109 was
cotransformed with the REPS2-bait and p65- or Clone4-
prey constructs as indicated in Table 1. Equal amounts
of the cotransformation mix were plated out on medium
that lacked tryptophan and leucine (only transformed
cells survive), and on medium that lacked tryptophan,
leucine, histidine and adenine (only transformants with
interaction between bait and prey survive). When the
REPS2 variants were cotransformed with empty prey
vector, none of the cotransformants were able to survive
the histidine and adenine selection (Table 1a; columns
TLHA). This means that the REPS2 baits alone
do not activate the histidine and the adenine marker in
the yeast genome. However, when the REPS2 variants
were cotransformed with the p65(74–551)-prey con-
struct, six out of seven cotransformations resulted in
yeast cotransformants that were able to grow on
histidine- and adenine-minus plates (Table 1b; columns
TLHA). All these six REPS2 variants have the
EH domain in common, indicating that this domain
of REPS2 binds to p65. When the REPS2 variants
were cotransformed with Clone4 (Table 1c), only the
cotransformants with a bait containing the C-terminal
part of REPS2 were able to survive the histidine and
adenine selection. These results show that the C-
terminal part of REPS2 (amino acids 451–659) binds
to Clone4, providing a control for specificity of binding
of the REPS2 EH domain to p65.
The EH domain of REPS2 binds the NPF motif region
of p65
The next step was to determine which region of p65
interacts with the EH domain of REPS2. An EH
domain is a conserved protein–protein interaction
domain, first identified in the tyrosine kinase substrate
Eps15 (Wong et al., 1995). Different studies showed that
EH domain-proteins preferentially bind to peptides or
proteins containing an asparagine–proline–phenylala-
nine (NPF) motif (Fazioli et al., 1993; Salcini et al.,
1997; Paoluzi et al., 1998), and such an NPF motif is
present in the NF-kB p65 fragment (at amino-acid
position 139–141). Alignment of human, mouse and
chicken p65 shows that this NPF is conserved
(Figure 2a). Furthermore, using structural NF-kB data
from the literature, it was shown that the NPF sequence
REPS2a(1-659)
REPS2a(140-659)(=REPS2b)
REPS2a(1-373)
REPS2a(140-373)
REPS2a(256-373)
REPS2a(256-659)
REPS2a(451-659)
EH domain
Proline-rich motifs
RalBP1-interacting region
Coiled coil
Figure 1 Schematic representation of seven REPS2 variants used in the present study
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Table 1 The EH domain of REPS2 binds p65(74–263)
Selection Selection
GAL4-DBD GAL4-AD TL TLHA
A REPS2a(1–659) Empty prey-vector + 
REPS2a(140–659) Empty prey-vector + 
REPS2a(1–373) Empty prey-vector + 
REPS2a(140–373) Empty prey-vector + 
REPS2a(256–373) Empty prey-vector + 
REPS2a(256–659) Empty prey-vector + 
REPS2a(451–659) Empty prey-vector + 
— Empty prey-vector + 
B REPS2a(1–659) p65(74–551) + +
REPS2a(140–659) p65(74–551) + +
REPS2a(1–373) p65(74–551) + +
REPS2a(140–373) p65(74–551) + +
REPS2a(256–373) p65(74–551) + +
REPS2a(256–659) p65(74–551) + +
REPS2a(451–659) p65(74–551) + 
— p65(74–551) + 
C REPS2a(1–659) Clone4 + +
REPS2a(140–659) Clone4 + +
REPS2a(1–373) Clone4 + 
REPS2a(140–373) Clone4 + 
REPS2a(256–373) Clone4 + 
REPS2a(256–659) Clone4 + +
REPS2a(451–659) Clone4 + +
— Clone4 + 
D REPS2a(1–659) p65(74–263) + +
REPS2a(140–659) p65(74–263) + +
REPS2a(1–373) p65(74–263) + +
REPS2a(140–373) p65(74–263) + +
REPS2a(256–373) p65(74–263) + +
REPS2a(256–659) p65(74–263) + +
REPS2a(451–659) p65(74–263) + 
— p65(74–263) + 
Yeast AH109 cells were cotransformed with REPS2-bait constructs combined with: (A) empty vector-prey, (B) p65(74–551)-prey, (C) Clone4-prey,
(D) p65(74–263)-prey. Equal amounts of the cotransformation mix were plated out on medium that lacked tryptophan and leucine (TL;
cotransformed cells survive) and on medium that lacked tryptophan, leucine, histidine and adenine (TLHA; only yeast cells with interaction
between bait and prey proteins survive). After 3 days the plates were scored for yeast colonies: (+)¼ colonies present; ()¼no colonies present
b c d
a
H. sapiens NLGIQCVKKRDLEQAISQRIQTNNNPFQVPIEEQRGDYDL 154
M. musculus NLGIQCVKKRDLEQAISQRIQTNNNPFHVPIEEQRGDYDL 154
G. gallus NLGIQCVKKRELEAAVAERIRTNNNPFNVPMEERGAEYDL 160
Figure 2 The NPF motif of p65 is present in the human, mouse and chicken proteins, and is located in a turn. (a) The p65 sequence
fromHomo sapiens,Mus musculus and Gallus gallus were aligned using the DNAMAN program. The red box indicates the NPF motif.
(b) Structure of an I-kBa/NF-kB complex (Huxford et al., 1998). The complex shown consists of a part of mouse p65 (pink and blue),
part of mouse p50 (brown) and part of human I-kBa (green). (c) Part of human p65 (pink) subunit from another
I-kBa/NF-kB complex (Jacobs and Harrison, 1998). (d) Part of mouse p65 (pink and blue) and part of mouse p50 (brown and
green) bound to the Ig/HIV-kB DNA site (grey and orange) (Chen et al., 1998). All three pictures were generated using the Cn3D 3D-
structure viewer, which is available at the NCBI website. The NPF amino-acid motif is highlighted in yellow
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is located in a turn at the surface of the p65 subunit
(Figure 2b–d). Similarly, using solution structure data of
two other EH–NPF complexes, the NPF was found to
be located in a turn when bound into the pocket of the
EH domain (De Beer et al., 2000). To collect experi-
mental data to support the hypothesis further, yeast
two-hybrid analysis was performed with p65(74–263),
a truncated version of p65(74–551), which is missing
288 C-terminal amino-acid residues. It was observed
that this truncated p65(74–263), which contains the
NPF sequence, is still able to bind to REPS2 variants
that contain the EH domain (Table 1d). This result
is in agreement with the hypothesis that the
p65-NPF motif is the site that binds to the EH domain
of REPS2.
Tryptophan 323 in the core of the EH domain is important
for REPS2–p65 binding in yeast
In Eps15, a tryptophan residue in the core of the second
EH domain is critical for interaction with a peptide
containing an NPF motif (De Beer et al., 1998). This
interaction was lost when the critical tryptophan residue
was replaced by an alanine residue, while substitution
by a tyrosine residue affected the binding only slightly
(De Beer et al., 1998). The respective tryptophan residue
is highly conserved among EH domains, and in REPS2
this residue is located at position 323. To examine
whether the conserved tryptophan at position 323 in the
EH domain of REPS2 is involved in the binding
between REPS2 and p65, this tryptophan was sub-
stituted for by either an alanine or a tyrosine residue in
REPS2b, and the interaction between these REPS2b
mutant proteins and p65 was measured in a quantitative
yeast two-hybrid assay. An almost complete loss of
reporter signal (beta-galactosidase activity) was ob-
served in yeast cells expressing the REPS2b(W323A)-
bait and p65(74–551)-prey, compared to yeast with the
wild-type REPS2b-bait and p65(74–551)-prey combina-
tion (Figure 3a). This would be in agreement with the
observations reported by De Beer et al. (1998). How-
ever, in the present experiments we found that the
interaction was also lost for the REPS2b(W323Y)-bait
(Figure 3a), which indicates that substitution of the
tryptophan 323 residue in the EH domain of REPS2 by
either an alanine or a tyrosine residue leads to loss of
interaction with NF-kB/p65.
Clone4 binds to the C-terminal region of REPS2b,
and it is unlikely that this interaction would be affected
by the two point mutations (REPS2b(W323A) and
REPS2b(W323Y), respectively). Indeed, wild-type and
the two mutant REPS2 baits were found to bind the
Clone4-prey construct with similar binding strength, as
indicated by a comparable betagalactosidase reporter
signal (Figure 3b).
Taken together, the results show that tryptophan 323 in
the EH domain of REPS2 is critical for binding of REPS2
to p65 in yeast, lending further support that the EH
domain of REPS2 binds the NPF motif(139–141) in p65.
REPS2 variants that have the EH domain and lack the
C-terminal region bind to p65(74–551) in COS-1 cells,
but none of the variants bind to p65 in LNCaP cells
From the literature it is known that NF-kB transcrip-
tion factors are absent in yeast, and bait–prey binding
between (putative) NF-kB pathway proteins in yeast,
therefore, does not involve endogenous NF-kB pathway
regulators. To study the interaction between REPS2 and
p65 in a mammalian environment, a two-hybrid assay
REPS2b
bait:
p65 interacting region
prey: p65(74-551)
0 2 4 6 8 10 12 14 16
beta gal units
REPS2b(W323A)
REPS2b(W323Y)
REPS2b
Clone4 interacting region
prey: Clone4
0 2 4 6 8 10
beta gal units
REPS2b(W323A)
REPS2b(W323Y)
a
b
W->Y
W->A
W->A
W->Y
bait:
**
**
Figure 3 Quantitative two-hybrid assay demonstrating that tryptophan 323 in REPS2 is important for binding to p65. Yeast strain
Y190 harboring the REPS2b-, the REPS2b(W323A)- or the REPS2b(W323Y)-bait in combination with the p65(74-551)-prey (a) or the
Clone4-prey (b) were cultured. From the cultures, extracts were prepared and b-galactosidase activity was measured. The figure shows
the average of three independent experiments for each combination. Differences between wild-type and mutant REPS2b were
considered significant (**) at Po0.01, as determined by paired Student’s t-tests
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was performed in COS-1 cells. Based on the results
obtained with the yeast two-hybrid assays (Table 1b), six
out of the seven REPS2 variants were expected to bind
to p65(74–551). However, using the mammalian two-
hybrid assay in COS-1 cells, only three REPS2-bait
variants bound to the p65(74–551)-prey, as indicated by
the binding signal (Figure 4a; prey: p65(74–551)).
Different factors might be responsible for the failure
of several REPS2-baits to generate a binding signal
when cotransfected with p65(74–551)-prey: the con-
structs may not be expressed; the bait-hybrid may not
be able to translocate to the nucleus; or REPS2, which
is known to induce apoptosis when overexpressed, may
also induce apoptosis under these particular circum-
stances. To exclude these possibilities, REPS2 variants
were also cotransfected with Clone4. It was observed
that Clone4 bound to all the REPS2 baits that contained
the C-terminal region (Figure 4a; prey: Clone4). These
results are in agreement with the data obtained from the
yeast two-hybrid assays (Table 1c) and show that all
REPS2 hybrid proteins are suitable as bait in the
mammalian two-hybrid assays in COS-1 cells.
To study the interaction between REPS2 and p65 in
human prostate cells, the mammalian two-hybrid assays
were also performed using the androgen-dependent
human prostate cancer cell line LNCaP. In contrast to
what was observed for COS-1 cells, none of the REPS2-
bait variants bound to the p65(74–551)-prey, as
indicated by lack of a binding signal (Figure 4b).
However, the control binding of REPS2-bait variants
to the Clone4-prey also gave negative results (Figure 4b),
so that we cannot exclude any possible confounding
factors, which may exert an effect in LNCaP cells.
REPS2–p65 and REPS2–Clone4 binding occurs
in LNCaP cells after stimulation with PMA
In COS-1 cells the luciferase signals obtained with
REPS2 and p65 were higher than the signals produced
by positive control binding between p53 and Large T
antigen (Figure 4a). In contrast, in LNCaP cells no
binding signal for REPS2–p65 or REPS2–Clone4 could
be detected, whereas the positive control showed a high
binding signal (Figure 4b). A possible explanation for
the lack of binding signal in the experimental bait–prey
assays in LNCaP cells is that LNCaP cells, compared to
COS-1 cells, may contain additional pathways that
suppress REPS2–p65 and REPS2–Clone4 interactions.
As p65 is a subunit of the NF-kB complex, it was
speculated that regulators of the NF-kB pathway could
play a role. To test this, mammalian two-hybrid assays
were conducted in the presence of the phorbol ester
PMA, an activator of the NF-kB pathway. It was
observed that for some variants of REPS2, binding to
p65 and Clone4 was highly induced by PMA (Figure 5).
Expression of REPS2b and p65, and control-binding
between p53 and Large T antigen was only marginally
affected by PMA, which indicates that the observed
effect was not due to increased protein expression, but
rather supports the idea that PMA modulates pathways
prey: p65(74-551)
0 50 100 150 200 250 300 350
luciferase activity (x10,000)
a
b
prey: Clone4
0 50 100 150 200 250
luciferase activity (x10,000)
(bait: p53 + prey: largeT)
R
EP
S2
 b
ai
ts
prey: p65(74-551)
0 100 200 300 400 500 600
luciferase activity (x1000)
R
EP
S2
 b
ai
ts
prey: Clone4
0 50 100 150 200 250 300 350 400 450 500
luciferase activity (x1000) 
(bait: p53 + prey: largeT)
Figure 4 REPS2–p65 and REPS2–Clone4 binding in COS-1 and LNCaP cells. REPS2 bait constructs (left side of the figure) and p65-
or Clone4-prey constructs (top of the figures) were cotransfected with the GAL4-luciferase reporter in COS-1 cells (a) or in LNCaP
cells (b). Besides these bait and prey constructs, the positive control constructs p53-bait and Large T antigen-prey were also used in this
assay. At 48 h after cotransfection, luciferase activity was measured in the cells. For each mammalian two-hybrid assay, two control
assays were conducted: empty bait vectorþ prey and baitþ empty prey vector. The control assays generated, compared to the
experimental assays, only a low luciferase signal. This experiment has been repeated three times, and the figure shows the data from one
representative experiment
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that stimulate binding of REPS2 to p65 and Clone4 in
LNCaP cells.
Tryptophane 323 in the core of the EH domain is
important for REPS2–p65 binding in mammalian cells
As shown in Figure 3, in yeast, tryptophan 323 in the
EH domain of REPS2(140–659) is important for
binding between REPS2(140–659) and p65(74–551).
The outcome of similar experiments using mammalian
COS-1 and LNCaP cells is shown in Figure 6. As
binding between the REPS2(1–373)-bait and the p65-
prey produced the highest luciferase signal in LNCaP
cells upon treatment with PMA (Figure 5a), this bait
was used in the mammalian two-hybrid assays. Figure
6a and b show that substitution of tryptophan 323 to
alanine has a dramatic effect on REPS2(1–373)–p65(74–
551) binding in COS-1 and LNCaP cells. When
tryptophan 323 was substituted for a tyrosine, however,
the effect on binding between REPS2(1–373) and
p65(74–551) was less severe in both cell lines. These
results are in agreement with the results obtained by De
Beer et al. (1998) for the binding between a mutated EH
domain and an NPF containing peptide (De Beer et al.,
1998). It should be noted that the background signals
(Figure 6a; panel on the right), which are produced by
wild-type REPS2a(1–373) and the two substitution
mutated baits, although less high, resembles the signals
that are obtained when p65 prey is cotransfected
(Figure 6a; panel on the left). Possibly, there is some
binding of an endogenous protein with transactivating
activity to the REPS2 baits. In fact, this endogenous
protein with transactivating capacity could very well be
p65. LNCaP cells probably have less endogenous p65
available for binding to the REPS2 baits (Figure 6b;
panel on the right).
Discussion
Using the yeast two-hybrid system, it was shown that
REPS2 was identified as a binding partner of the NF-kB
subunit RelA/p65. Furthermore, it was demonstrated
that the Eps15 homology domain within REPS2 (EH
domain, located at amino acids 265–366) is responsible
for this interaction. It has been described that EH
domain-proteins preferentially bind to peptides or
proteins containing an asparagine–proline–phenylala-
nine (NPF) motif (Fazioli et al., 1993; Salcini et al.,
1997; Paoluzi et al., 1998), and the p65 sequence
contains such an NPF sequence at amino acids 139–
141. Using crystal structure data from the literature
(Chen et al., 1998; Huxford et al., 1998; Jacobs and
Harrison, 1998), it was determined that the NPF in p65
is located at the surface of the protein in a turn of a
loop. The position of the NPF in p65 is in agreement
with protein-structure data from De Beer et al. (2000),
and suggests that the NPF domain can act as a docking
site for proteins like REPS2. Experimental data
provided further back-up for this hypothesis: when a
large portion of p65 was deleted, the yeast two-hybrid
assay still showed normal interaction between the EH
domain of REPS2 and p65(74–263). Additional support
Figure 5 REPS2–p65 and REPS2–Clone4 binding occurs in LNCaP cells after stimulation with PMA. The assays in this figure were
performed in the same way as described for Figure 4, except that 24 h after transfection the cells were treated with 10 ng/ml PMA or
vehicle
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came when the role of a highly conserved tryptophan
in the core of the REPS2 EH domain was studied in
quantitative yeast two-hybrid assays. In agreement with
De Beer et al. (1998), it was shown that this tryptophan
in the EH domain of REPS2 is critical for binding to the
NPF-containing protein sequence of p65.
Although the data obtained with the yeast two-hybrid
system demonstrated that REPS2 is able to bind to p65,
it cannot be concluded that this interaction has a
physiological role in the cell. Therefore, the interaction
was studied also in mammalian cells, and it was
observed that there are significant differences between
REPS2–p65 binding in yeast as compared to mamma-
lian cells. First, it was observed that not all REPS2
variants, which – on the basis of the yeast data were
thought to interact with p65 – did interact in COS-1
cells. In fact in mammalian cells, the C-terminal part of
REPS2 was found to inhibit the interaction between
REPS2 and p65. Second, in the human prostate cancer
cell line LNCaP, all interactions between EH domain-
containing variants of REPS2 and p65 are below
detection level. Because p65 is part of the NF-kB
complex, it was speculated that NF-kB pathway
regulators may suppress REPS2–p65 interaction in
LNCaP cells. To modify the activity of NF-kB pathway
regulators the assays were conducted in the presence of
PMA, which is an activator of the NF-kB pathway. In
line with the observations for COS-1 cells, it was
observed that in LNCaP cells, in the presence of
PMA, significant binding occurred between REPS2
and p65.
As indicated in the Introduction, REPS2 expression is
significantly reduced in androgen-independent prostate
cancer (Chang et al., 1997; Oosterhoff et al., 2003).
Based on these findings, and in view of indications that
REPS2 is involved in growth factor signaling (Naka-
shima et al., 1999), it was hypothesized that REPS2
might play a role in the transition of prostate cancer
from androgen-dependent towards androgen-indepen-
dent growth. Therefore, the newly identified interaction
between REPS2 and the NF-kB subunit p65 could also
be of importance for our understanding of prostate
cancer progression. During prostate cancer progression,
and parallel to loss of REPS2 expression, the NF-kB
pathway becomes much more active (Palayoor et al.,
1999; Chen and Sawyers, 2002). In a developing cancer,
activation of the NF-kB pathway would provide the
cells with additional cell survival proteins (Van Antwerp
et al., 1996; Wang et al., 1996; Sumitomo et al., 1999).
For example, Mayo et al. (1997) showed that cells stably
transfected with an oncogenic form of Ras die when the
NF-kB pathway is blocked. In case of prostate cancer,
activation of the NF-kB pathway would imply that the
developing cancer becomes much more resistant to
removal of androgens (androgen-ablation therapy).
Figure 7 shows a sequence of events that may illustrate
different and subsequent stages in the development of
prostate cancer. Three stages of prostate cancer are
depicted. In Figure 7a, an oncogenic signal induces cell
growth and cell death pathways in prostate cells.
Because, for unknown reasons, the cell death signal is
to weak, the prostate cells develop into cancer cells. In
Figure 7b, cell death is stimulated because the cancer
cells are treated with androgen ablation therapy. The
NF-kB pathway cannot prevent this therapy-induced
apoptosis, because the pathway is inhibited by REPS2.
In Figure 7c, some prostate cancer cells manage to
escape cell death with the help of additional cell survival
proteins. The observed downregulation of REPS2
during this stage of the disease could be responsible
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b
Figure 6 The conserved tryptophan in the EH domain of REPS2 is important for REPS2–p65 binding in mammalian cells.
REPS2a(1–373), REPS2a(1–373)(W323A) and REPS2a(1–373)(W323Y) were used as baits in mammalian two-hybrid assays. COS-1
(top) and LNCaP cells (bottom) were cotransfected with reporter, bait and p65(74–551)-prey construct (left side), or the empty-prey
vector (right side), as indicated in the figure. (a) COS-1 cells were left untreated for 48 h, and then luciferase activity was measured.
(b) LNCaP cells were treated with PMA or vehicle starting at 24 h after transfection, and assayed for luciferase activity 48 h after
transfection
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for, or contribute to, upregulation of cell survival
proteins through loss of inhibition of the NF-kB
pathway.
Many reports in literature describe an antiapoptotic
role for the NF-kB pathway; however, there are also
some reports that show a proapoptotic role for the NF-
kB pathway. In case of prostate cancer for example,
Ling et al. (2003) showed that increased NF-kB pathway
activity in LNCaP cells promotes cell survival, whereas
Kimura and Gelmann (2002) showed a proapoptotic
effect of NF-kB signalling in the same cell line. As the
NF-kB pathway is highly active in androgen-indepen-
dent prostate cancer (Palayoor et al., 1999; Chen and
Sawyers, 2002), and this activity does not result in cell
death, the antiapoptotic effect of NF-kB is depicted
in the model (Figure 7). Besides a role in regulating
apoptosis, active NF-kB is also able to stimulate
proliferation through upregulation of genes that are
involved in cell growth (Figure 7c). For example,
recently it has been shown that the activated NF-kB
pathway, in androgen-independent prostate cancer cells,
is important for upregulation of interleukin-6 (IL-6)
(Park et al., 2003; Zerbini et al., 2003). Since IL-6 has
also been reported to stimulate growth of prostate
cancer cells (Steiner et al., 2003), these cells will become
more and more independent of growth factors and
androgens.
The molecular mechanism through which down-
regulation of the REPS2 protein contributes to upregu-
lation of NF-kB activity is not clear at the moment.
Because proteins with which REPS2 interacts are all
cytoplasmic in localization (Grb2, RalBP1, Epsin,
Eps15) and because REPS2 itself was also reported to
be located predominantly in the cytoplasm (Oosterhoff
et al., 2003), the interaction between REPS2 and p65
probably takes place in the cytoplasm. It can be
speculated that REPS2 may inhibit NF-kB activity by
retaining p65 in the cytoplasm, but the exact mechanism
needs to be studied further.
The NF-kB pathway is constitutively active in many
advanced tumours, and is considered a potential target
for cancer drug development (Garg and Aggarwal, 2002).
Since the mechanisms that are responsible for high NF-
kB activity in tumours are not known, studies on the
REPS2–p65 interaction may provide additional infor-
mation with regard to control of activity of the NF-kB
pathway during progression of prostate and potentially
other cancers.
Materials and methods
Constructs
The complete REPS2a ORF (Oosterhoff et al., 2003) was used
as a template to amplify the seven REPS2 variants (Figure 1).
In order to facilitate subcloning, an EcoRI site was added
to the N-terminal primers and a SalI site to the C-terminal
primers. The Zero Blunt TOPO PCR Cloning Kit (Invitrogen
Life Technologies, Carlsbad, CA, USA) was used to clone the
PCR products into the pCR-Blunt II-TOPO vector. The
REPS2 variants were subsequently subcloned, using the EcoRI
and SalI sites, into the pGBKT7 (the bait vector from the BD
Matchmaker Two-Hybrid System 3, BD Biosciences Clontech,
Palo Alto, CA, USA) and into the pM vector (the bait vector
from BD Matchmaker Mammalian Two-Hybrid Assay Kit,
BD Biosciences Clontech). All seven REPS2 variants have
been sequenced. The QuikChange XL Site-Directed Mutagen-
esis Kit (Stratagene, La Jolla, CA, USA) was used to construct
the REPS2 fragments containing the W323A and W323Y
pointmutations. The isolated yeast two-hybrid prey plasmids
pACT2clone4 (unknown hypothetical protein) and the
pACT2clone8 (encodes for p65(74–551)) were used as template
to PCR the Clone4 fragment and the p65 fragment. Again, to
facilitate subcloning an EcoRI site was added to the N-
terminal primer for the Clone4 fragment and a SalI site to the
C-terminal primer. For the p65 fragment N-terminal a BamHI
site was introduced and C-terminal a HindIII site. The PCR
fragments were cloned into the pCR-Blunt II-TOPO vector
and subsequently subcloned into the pVP16 vector (the prey
vector from the Mammalian two-hybrid system, BD Bio-
sciences Clontech). DNA was isolated using the QIAprep Spin
Miniprep Kit (QIAGEN GmbH, Hilden, Germany) and the
DNA Gel Extraction Kit from Millipore (Millipore Corpora-
tion, Bedford, MA, USA) was used to isolate fragments from
gel. The Rapid DNA Ligation Kit (Roche, Mannheim,
Germany) was used for the ligation reactions.
Yeast two-hybrid screen
The BD Matchmaker Two-Hybrid System 3 (BD Biosciences
Clontech) was used for the yeast two-hybrid screen. The
pGBKT7-REPS2a bait construct was introduced into the S.
cerevisiae AH109 strain and protein expression was verified on
Western blot (not shown). The AH109 strain with the REPS2a
bait was used to screen the Human Prostate Matchmaker
cDNA Library (BD Biosciences Clontech). The screening was
performed as described in the BD Matchmaker Two-Hybrid
System 3 manual, with the exception that carrier DNA from
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NF-kappaB 
cell death 
cell growth 
no androgen ablation 
therapy 
Active REPS2 
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NF-kappaB 
cell death 
cell growth 
effective androgen 
ablation therapy 
REPS2 down-regulated
oncogenic signal 
NF-kappaB 
cell death 
cell growth 
ineffective androgen 
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a
c
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?
Figure 7 Lack of the REPS2–p65 interaction in relation to
prostate cancer. (a, b) Androgen-dependent prostate cancer. The
growth signal overrules the endogenous cell death signal (a).
However, upon ablation of androgens an additional cell death
signal is activated and the cells die of apoptosis (b). In androgen-
independent prostate cancer (c), REPS2 expression is relatively
low. Lack of REPS2–p65 (NF-kB subunit) interaction is hypothe-
sized to contribute to constitutive activity of the NF-kB pathway.
This constitutive activity could then be responsible for expression
of extra cell survival proteins (CSP), which would result in survival
of prostate cancer cells during androgen ablation
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Salmon Testes was used (Sigma-Aldrich Corporation, St
Louis, MI, USA). From yeast cells that survived binding
selection the prey plasmid was rescued according to the
protocol described by Hoffman and Winston (1987).
Yeast two-hybrid assays
The S. cerevisiae AH109 strain was used in the qualitative
yeast two-hybrid assays as shown in Table 1. The AH109 yeast
strain was cotransformed, with the appropriate bait and prey
vectors, according the Quick and Easy TRAFO Protocol
(Gietz and Woods, 2002). Since the AH109 strain has low
expression of the lacZ reporter gene the S. cerevidiae Y190
strain, which has high expression of the lacZ gene, was used in
the quantitative yeast two-hybrid assays as shown in Figure 3.
A liquid culture assay, which used ONPG as substrate (Yeast
Protocols Handbook; BD Biosciences Clontech manual
PT3024-1), was used to measure the activity of the lacZ
reporter. Because the Y190 is relatively difficult to cotransform
the Y190 strain was first transformed with the appropriate
prey vector and then the appropriate bait vector was
introduced.
Mammalian two-hybrid assays
The BDMatchmaker Mammalian Two-Hybrid Assay Kit (BD
Biosciences Clontech) was used for the mammalian two-hybrid
assays. Instead of the pSG5CAT reporter vector, which is the
reporter from the Mammalian Two-Hybrid Assay Kit, a 5
GAL4 binding site-luciferase reporter was used. COS-1 and
LNCaP cells were cotransfected using Fugene 6 Transfection
Reagent (Roche, Indianapolis, IN, USA) with 200 ng DNA
mix (80 ng bait, 80 ng prey and 40 ng reporter) per well of a 24
wells plate. PMA (phorbol 12-myristate 13-acetate, Sigma-
Aldrich Corporation) was dissolved in 100% ethanol and used
in a 10 ng/ml concentration. COS-1 cells were maintained in
DMEM/F12 containing 5% dextran-coated charcoal treated
fetal calf serum (DCC-FCS). LNCaP were maintained in
RPMI 1640 containing 10% fetal calf serum (FCS) and were
used between passages 27 and 37. Both cell lines were cultured
at 371C in a 5% CO2 atmosphere and standard antibiotics
were added to the media. Luciferase activity was determined
48 h after the start of transfection with the Topcount NXTt
microplate luminescence counter (Packard Bioscience BV;
Meriden, CT, USA). Cells were lysed with a standard
luciferase lysis buffer and subsequently a part of the lysate
was transferred to the Topcount 96 wells microplate. Just prior
to the measurement, Steady Glo substrate (Promega, Madison,
WI, USA) dissolved in Steady Glo buffer was added to the
wells.
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